MX2017014134A - Procedimiento para la preparacion de 2- { 4- [2- ( { [2- (4-clorofenil) -1, 3-tiazol-4-il]metil} sulfanil) -3,5-diciano-6- (pirrolidin-1-il) piridina-4-il] fenoxi } etil-l-alanil-l-alaninat o-monohidrocloruro. - Google Patents

Procedimiento para la preparacion de 2- { 4- [2- ( { [2- (4-clorofenil) -1, 3-tiazol-4-il]metil} sulfanil) -3,5-diciano-6- (pirrolidin-1-il) piridina-4-il] fenoxi } etil-l-alanil-l-alaninat o-monohidrocloruro.

Info

Publication number
MX2017014134A
MX2017014134A MX2017014134A MX2017014134A MX2017014134A MX 2017014134 A MX2017014134 A MX 2017014134A MX 2017014134 A MX2017014134 A MX 2017014134A MX 2017014134 A MX2017014134 A MX 2017014134A MX 2017014134 A MX2017014134 A MX 2017014134A
Authority
MX
Mexico
Prior art keywords
dicyano
sulfanyl
thiazol
pyrrolidin
chlorophenyl
Prior art date
Application number
MX2017014134A
Other languages
English (en)
Inventor
Mais Franz-Josef
Keil Birgit
Olenik Britta
Meibom Daniel
Heilmann Werner
Becker Guido
Kuhlmann Thomas
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2017014134A publication Critical patent/MX2017014134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente solicitud se refiere a un procedimiento nuevo y mejorado para la preparación del compuesto 2-{4[2-({[2-(4-clorofen il)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-i l)piridina-4-il]fenoxi}etil-L-alanil-L-alaninato-monohidrocloruro de la fórmula (I), (ver Fórmula) nuevas fases previas para su preparación y la preparación y uso de la modificación cristalina I de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3 ,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-L-alanil- L-alaninato-monohidrocloruro de la fórmula (I).
MX2017014134A 2015-05-06 2016-05-02 Procedimiento para la preparacion de 2- { 4- [2- ( { [2- (4-clorofenil) -1, 3-tiazol-4-il]metil} sulfanil) -3,5-diciano-6- (pirrolidin-1-il) piridina-4-il] fenoxi } etil-l-alanil-l-alaninat o-monohidrocloruro. MX2017014134A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166606 2015-05-06
EP15192030 2015-10-29
PCT/EP2016/059779 WO2016188711A1 (de) 2015-05-06 2016-05-02 Verfahren zur herstellung von 2-{4-[2-({[2-(4-chlorphenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyan-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninat-monohydrochlorid

Publications (1)

Publication Number Publication Date
MX2017014134A true MX2017014134A (es) 2018-03-15

Family

ID=55969107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014134A MX2017014134A (es) 2015-05-06 2016-05-02 Procedimiento para la preparacion de 2- { 4- [2- ( { [2- (4-clorofenil) -1, 3-tiazol-4-il]metil} sulfanil) -3,5-diciano-6- (pirrolidin-1-il) piridina-4-il] fenoxi } etil-l-alanil-l-alaninat o-monohidrocloruro.

Country Status (32)

Country Link
US (1) US20180155336A1 (es)
EP (1) EP3292133B1 (es)
JP (1) JP2018516882A (es)
KR (1) KR20180002698A (es)
CN (1) CN107531688A (es)
AU (1) AU2016268920A1 (es)
BR (1) BR112017023852A2 (es)
CA (1) CA2984984A1 (es)
CL (1) CL2017002764A1 (es)
CO (1) CO2017011294A2 (es)
CU (1) CU20170136A7 (es)
DK (1) DK3292133T3 (es)
EA (1) EA201792422A1 (es)
EC (1) ECSP17072780A (es)
ES (1) ES2744227T3 (es)
HK (1) HK1246290A1 (es)
HR (1) HRP20191596T1 (es)
HU (1) HUE044787T2 (es)
IL (1) IL255208A0 (es)
LT (1) LT3292133T (es)
MA (1) MA42039A (es)
MX (1) MX2017014134A (es)
PE (1) PE20180204A1 (es)
PH (1) PH12017502010A1 (es)
PL (1) PL3292133T3 (es)
PT (1) PT3292133T (es)
SG (1) SG11201708747PA (es)
SI (1) SI3292133T1 (es)
TN (1) TN2017000466A1 (es)
TW (1) TW201713651A (es)
UY (1) UY36664A (es)
WO (1) WO2016188711A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108884A1 (de) 2016-12-16 2018-06-21 Bayer Pharma Aktiengesellschaft Pharmazeutische tablettenformulierung
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
TWI721449B (zh) * 2019-06-11 2021-03-11 行政院原子能委員會核能研究所 2-[[2-[[[3-(4-氯苯基)-8-甲基-8-氮雜雙環[3.2.1]-辛-2-基]-甲基](2-巰基乙基)胺基]乙基]胺基]乙硫醇-[1r(外向-外向)]三鹽酸化物之純化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
ECSP17072780A (es) 2017-12-01
SI3292133T1 (sl) 2019-08-30
US20180155336A1 (en) 2018-06-07
CL2017002764A1 (es) 2018-05-25
TW201713651A (zh) 2017-04-16
ES2744227T3 (es) 2020-02-24
PH12017502010A1 (en) 2018-03-26
HUE044787T2 (hu) 2019-11-28
PL3292133T3 (pl) 2019-12-31
UY36664A (es) 2016-11-30
HK1246290A1 (zh) 2018-09-07
IL255208A0 (en) 2017-12-31
BR112017023852A2 (pt) 2018-07-17
TN2017000466A1 (en) 2019-04-12
CA2984984A1 (en) 2016-12-01
PT3292133T (pt) 2019-09-18
KR20180002698A (ko) 2018-01-08
CN107531688A (zh) 2018-01-02
WO2016188711A1 (de) 2016-12-01
CU20170136A7 (es) 2018-02-08
CO2017011294A2 (es) 2018-01-16
JP2018516882A (ja) 2018-06-28
PE20180204A1 (es) 2018-01-31
EP3292133A1 (de) 2018-03-14
EP3292133B1 (de) 2019-06-26
DK3292133T3 (da) 2019-09-23
SG11201708747PA (en) 2017-11-29
EA201792422A1 (ru) 2018-02-28
AU2016268920A1 (en) 2017-11-09
MA42039A (fr) 2018-03-14
HRP20191596T1 (hr) 2019-11-29
LT3292133T (lt) 2019-08-26

Similar Documents

Publication Publication Date Title
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
WO2014132270A3 (en) Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
MX347692B (es) Inhibidores del virus de la hepatitis c.
PH12017502010A1 (en) Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride
WO2013111163A3 (en) Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2015124764A8 (en) Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate
WO2012147098A3 (en) Novel process for preparation of 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide
WO2015128875A3 (en) A process for preparation of dabigatran etexilate mesylate and intermediates thereof
IL257463A (en) Novel crystalline form of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxole -5-yl) cyclopropanecarboxamido)-3-methylpyridine-2-yl) benzoic acid and process of preparation thereof
IN2013CH04511A (es)
MX2020012771A (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
WO2014049612A3 (en) Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts
MX2016012485A (es) Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h -imidazo[4,5-b]piridin-2-il)piridin-2-amina.
WO2014049586A3 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
MX2021002875A (es) Formas cristalinas de un compuesto de quinazolina y sus sales clorhidrato.
MX2017004359A (es) Composiciones farmaceuticas que comprenden alpelisib.
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2014125233A3 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
WO2014020546A3 (en) Crystalline forms of dabigatran etexilate and process for their preparation
AR104502A1 (es) Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro
WO2017037743A3 (en) Dabigatran etexilate 1,4-butanedisulfonate salt and its crystal form
MX2015006806A (es) Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida.
IN2013CH06150A (es)
WO2015102019A3 (en) Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride